Raymond James Financial Services Advisors Inc. grew its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 46.6% during the third quarter, Holdings Channel reports. The institutional investor owned 74,401 shares of the biopharmaceutical company’s stock after purchasing an additional 23,637 shares during the quarter. Raymond James Financial Services Advisors Inc.’s holdings in Ocular Therapeutix were worth $234,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Summer Road LLC grew its stake in shares of Ocular Therapeutix by 0.4% during the fourth quarter. Summer Road LLC now owns 6,122,089 shares of the biopharmaceutical company’s stock valued at $17,203,000 after buying an additional 27,328 shares during the last quarter. BlackRock Inc. boosted its holdings in shares of Ocular Therapeutix by 7.0% during the second quarter. BlackRock Inc. now owns 5,262,920 shares of the biopharmaceutical company’s stock worth $27,157,000 after purchasing an additional 344,611 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Ocular Therapeutix by 2.9% during the first quarter. Vanguard Group Inc. now owns 4,195,406 shares of the biopharmaceutical company’s stock worth $20,768,000 after purchasing an additional 116,383 shares during the period. Deltec Asset Management LLC boosted its holdings in shares of Ocular Therapeutix by 4.4% during the third quarter. Deltec Asset Management LLC now owns 2,061,797 shares of the biopharmaceutical company’s stock worth $6,474,000 after purchasing an additional 87,000 shares during the period. Finally, State Street Corp boosted its holdings in shares of Ocular Therapeutix by 5.6% during the second quarter. State Street Corp now owns 1,576,213 shares of the biopharmaceutical company’s stock worth $8,133,000 after purchasing an additional 83,254 shares during the period. 54.42% of the stock is owned by institutional investors.
Ocular Therapeutix Stock Performance
Shares of OCUL opened at $4.92 on Wednesday. The company has a debt-to-equity ratio of 9.41, a current ratio of 4.03 and a quick ratio of 3.96. Ocular Therapeutix, Inc. has a one year low of $2.00 and a one year high of $7.96. The company has a 50-day simple moving average of $3.89 and a two-hundred day simple moving average of $3.58. The firm has a market capitalization of $390.75 million, a PE ratio of -4.32 and a beta of 1.02.
Analysts Set New Price Targets
A number of analysts have recently weighed in on OCUL shares. StockNews.com lowered shares of Ocular Therapeutix from a “hold” rating to a “sell” rating in a report on Monday. HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of Ocular Therapeutix in a report on Wednesday, October 4th.
Ocular Therapeutix Company Profile
Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
- Five stocks we like better than Ocular Therapeutix
- Your Comprehensive Guide to Investing in Bank Stocks
- Does UPS stock going down present an opportunity?
- How to Find Undervalued Stocks
- The truth behind Williams-Sonoma stock drop
- Industrial Products Stocks Investing
- Is Airbnb a buy on fee increase, international growth?
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.